Global Newsroom

KING OF PRUSSIA, Pa.

- Reduction in number of attacks is leading factor when evaluating prophylactic therapy

KING OF PRUSSIA, Pa. and PHILADELPHIA, Pa.

- 6 Urban League Affiliates across U.S. to participate -- starting with Philadelphia

KING OF PRUSSIA, Pa.

Global biotherapeutics leader reinforces commitment to cardiovascular research: Hosts Learning Studio with prominent cardiovascular thought leaders to discuss emerging treatment targets

KING OF PRUSSIA, Pa.

The AEGIS-II trial is evaluating the efficacy and safety of CSL112 (apolipoprotein A-1 [human]) during the high-risk 90-day period following a heart attack

KING OF PRUSSIA, Pa.

• Both US and European regulators grant special designation
• Phase 1 clinical development underway for CSL889

KING OF PRUSSIA, Pa.

- Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year

MELBOURNE, AU and KING OF PRUSSIA, PA

• Vaccine, hyperimmune and monoclonal antibodies all in clinical stages as potential preventative or treatment options in the fight against COVID-19

• Advancements across Cell and Gene Therapy, Recombinant Technology, Plasma Fractionation and Cell and Egg-Based Vaccines scientific platforms all spotlighted including internal progression, acquisitions and alliances

Osaka, JAPAN and King of Prussia, Pa., USA

• The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is under evaluation as part of the trial and may become one of the earliest treatments for hospitalized individuals at risk for serious complications of COVID-19
• The CoVIg-19 Plasma Alliance urges anyone who has recovered from COVID-19 to consider donating plasma. To learn more, please visit TheFightIsInUs.org

Here is how CSL Behring is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19

CSL continues to provide medicines to patients around the world.

KING OF PRUSSIA, PA
HAEGARDA is the first and only subcutaneous prophylactic HAE treatment approved for children 6 years of age and older

MARBURG, Germany

- Bronze sponsor CSL Behring also establishes programme for attendees to support Alpha 1 disease awareness

• On behalf of the CoVIg-19 Plasma Alliance and other plasma companies, Perreault urges people who have recovered from COVID-19 to consider donating plasma. To learn how and where to donate plasma, please visit TheFightIsInUs.org.

• The more convalescent plasma the industry collects – and the more quickly it does so – directly influences the timeline to deliver a potential hyperimmune globulin for COVID-19.

• The clinical trial, sponsored by The National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH), in which the CoVIg-19 Plasma Alliance will participate is expected to begin soon.

KING OF PRUSSIA, Pa.

• Five coagulation researchers named this year’s recipients
• Professor Heimburger Awards and ISTH Virtual Congress sponsorship showcase CSL Behring’s commitment to hematology research

KING OF PRUSSIA, Pa.

- Phase II placebo-controlled study will assess the safety and efficacy of CSL312 for the treatment of patients with severe respiratory distress due to COVID-19 related pneumonia
- CSL Behring now evaluating 5 approaches to preventing and treating COVID-19

KING of PRUSSIA, Pa.

• Unique gene therapy has the potential to be one of the first to market treatments to provide potentially long-term benefits with only one dose
• CSL Behring builds on legacy of delivering innovative treatment options for people with Hemophilia B

PHILADELPHIA

King of Prussia, Pa

Global bleeding disorders community will connect and discuss treatment advances June 14-19, 2020

KING OF PRUSSIA, Pa

• Builds on CSL Behring’s promise and commitment to the transplant community
• Deal accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for treatment of chronic active antibody-mediated rejection, into CSL Behring’s portfolio

HATTERSHEIM, Germany

Investigational Monoclonal Antibody Granted U.S. FDA Orphan Drug Designation